News

Patients in the study will receive CS-917, placebo, or an active comparator for a period of three months. CS-917 is a first-in-class, orally active, inhibitor of FBPase, an

The drug candidate, known as LY2275796, targets eIF-4E, a protein that is increased in a variety of cancers, including breast, head and neck, prostate, lung, bladder, colon, thyroid

The primary endpoint for the trial is objective disease response which will be evaluated using standardized criteria. Secondary objectives for the study include evaluation of safety, time to

Total payments could reach $577 million over the life of the project depending upon the successful completion of specified development, regulatory, and commercialization goals. Nastech will receive an

Fast track designation is reserved for new drugs that demonstrate the potential to address a significant unmet medical need and are intended for the treatment of a serious

The transaction provides Angiotech with a commercial platform to capitalize on its current product pipeline, supporting a wide range of specialty therapeutic areas. At the same time, the

Organon intends to use Medarex’s UltiMAb human antibody development system, which allows for the discovery of fully human antibodies in mice, to generate therapeutic antibodies against a variety

Amitiza is the first selective chloride channel activator approved for therapeutic use and has been shown to offer effective relief of chronic idiopathic constipation in adults. This condition

Locus, a computationally-based drug design and development company, has entered into the agreement with Lilly, however specific details of the collaboration were not disclosed. Protein kinases function as